We provide novel evidence that empagliflozin treatment for five weeks in HFD-fed ApoE(-/-) mice can attenuate NAFLD by not only improving metabolism and inflammation progression but also by promoting autophagy, reducing HFD-induced ER stress and inhibiting hepatocyte apoptotic processes. This evidence concerns the gene APOE and metabolic dysfunction-associated steatotic liver disease.